Genetherapy

Story Summary: (NASDAQ: MRNA), a leading RNAi-based drug discovery and development company, today announced the extension and expansion of its collaboration with the Vancouver Prostate Centre (VPC), covering the discovery and development of RNAi-based therapeutics for the treatment of bladder cancer. Research conducted by scientists and surgeons from both institutions demonstrated that MDRNAs UsiRNA targeting human survivin and delivered via DiLA2 liposomes achieved up to 90% target knockdown in a mouse model of orthotopic bladder cancer. The VPC is a National Centre of Excellence for translational research located at the University of British Columbia and the Vancouver General Hospital. In the case of the UsiRNA, UNA is substituted for specific nucleotides in both the guide and passenger strands. UsiRNAs are fully recognized by the cellular RNAi machinery, as demonstrated by their potent activity. MDRNA has also shown that substitution of UNA for specific RNA increases stability to nucleases, substantially reduces cytokine induction, and reduces passenger and guide strand-mediated offtarget effects. The DiLA2 Platform enables MDRNA to tailor the charge, linker length, and acyl chain characteristics to improve delivery of the liposomes to target tissue of interest. In addition, the platform is designed to permit attachment of peptides and other targeting molecules for delivery to a variety of tissues, and thus provide for a diverse therapeutic portfolio. SourceMDRNA, Inc. Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. Contact Our News EditorsFor any corrections of factual information, or to contact the editors please use our feedback form. Stages of Breast CancerBreast cancer stages tell us the characteristics of the cancer and if it has spread beyond the breast tissue. Living with Breast CancerThere are many options for treating breast cancer, including surgery, hormonal treatments, radiation and chemotherapy….Read the Full Story

Related posts:

1. MDRNA Reports UsiRNA Reduces Tumor Growth In Vivo
2. MDRNA, Inc. Reports Effective Local Delivery of a UsiRNA in an In Vivo Model of Bladder Cancer
3. PipelineReview.com – Biotech News & Online Store – MDRNA Reports Its Proprietary RNAi-Based Compounds Are Well Tolerated and Demonstrate High Potency Against Multiple Targets in Preclinical Studies